Chindex International, Inc. Chindex International, Inc. http://chinasecurities.com/ir/ChindexInternational en-US 08 Nov 2010 11:00:00 GMT 10 Feb 2012 14:36:15 GMT [Press Release] Reports Second Quarter and First Half Fiscal 2011 Financial Results message_5560 08 Nov 2010 11:00:00 GMT http://chinasecurities.com/ir/ChindexInternational/messages/5560 BETHESDA, Md., Nov. 8, 2010 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq:CHDX - News), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced financial results for the second quarter and first half of fiscal year 2011, which ended September 30, 2010.

  • Revenue in the second quarter of fiscal 2011 increased 18.6% to $45.2 million from $38.1 million in the second quarter of fiscal 2010;
  • Net income in the second quarter of fiscal 2011 was $3.2 million, or $0.20 per diluted share, compared to net income of $538,000, or $0.03 per diluted share, in the second quarter of fiscal 2010.
  • Revenue in the first half of fiscal 2011 increased 3.8% to $86.7 million from $83.5 million in the first half of fiscal 2010;
  • Net income in the first half of fiscal 2011 increased to $4.1 million, or $0.26 per diluted share, from $3.8 million, or $0.24 per diluted share, in the year over year period.


Second Quarter 2011 Financial Results

Revenue in the second quarter of fiscal 2011 reflected continued growth in the Healthcare Services division and Medical Products division. Revenue from the Healthcare Services division increased 11.4% to $23.4 million from $21.0 million in the prior year period, and reflects growing inpatient and outpatient volume across the United Family Healthcare network. Revenue from the Medical Products division increased 27.5% to $21.8 million from $17.1 million in the prior year period, and mainly reflects stronger second quarter demand for imaging products. Total revenue increased 18.6% to $45.2 million from $38.1 million in the second quarter of fiscal year 2010.

Income from operations in the second quarter of fiscal 2011 was $4.8 million, compared to income from operations of $1.4 million in the same quarter last year. Total operating costs and expenses for the second quarter of fiscal 2011 increased to $40.3 million compared to $36.7 million in the prior year period but decreased as a percentage of revenue to 89.3% from 96.3%. This primarily reflects cost containment in the Medical Products division and general and administrative expenditure commensurate with revenue growth in the Healthcare Services division.

Operating expenses in the second quarter of fiscal 2011 include the benefit of a $1.1 million unrealized foreign exchange gain compared to a $613,000 unrealized foreign exchange gain in the same quarter of the prior year. The unrealized exchange gain was recognized as a result of the strength of the Euro against the U.S. Dollar during the period, which impacted the translated value of intercompany debt owed from the Company's German subsidiary to the U.S parent company.

Operating expenses also included $375,000 of non-cash stock compensation expense compared to $852,000 in the prior year. Development, startup, and post-opening expenses in the Healthcare Services division were $653,000 in the period compared to $313,000 in the prior year.

Income from operations before foreign exchange in the second quarter of fiscal 2011 was $3.7 million, compared to $800,000 in the prior year period.

The Company recorded a $1.5 million provision for taxes, an effective tax rate of 31.6%, in the second quarter of fiscal 2011 as compared to a provision for taxes of $1.0 million, or an effective tax rate of 65.2%, in the prior year period. The effective tax rate in the prior period reflected losses in entities for which the Company could not recognize a tax benefit.

Net income for the quarter ended September 30, 2011 was $3.2 million, or $0.20 per diluted share. This compares to net income of $538,000, or $0.03 per diluted share, in the prior year period.

Healthcare Services division business results:

In the second quarter of fiscal year 2011, revenue increased 11.4% to $23.4 million from $21.0 million in the prior year period. The increase reflects continued growth of inpatient and outpatient volume across the Company's United Family Healthcare network.

In the second quarter of fiscal 2011, operating costs increased 6.0% to $19.9 million, a rate commensurate with revenue growth and inclusive of additional staffing efforts in advance of new facility openings. Income from operations before foreign exchange increased 47.8% to $3.4 million from $2.3 million in the prior year period.

Roberta Lipson, President and CEO of Chindex, stated, "Our performance this quarter reflects ongoing demand for services across our network. Volumes in Shanghai and Guangzhou continue to validate that we are replicating the UFH brand in these newer locations. We are on-track to more than double our capacity in the Beijing hospital by calendar year-end, and we intend to start accepting patients into our New Hope cancer facility in the next several weeks."

Medical Products division business results:

In the second quarter of fiscal 2011, the Company reported revenue from the Medical Products division of $21.8 million compared to $17.1 million in the prior year period. Revenue increased 27.5% on a year over year basis and reflects strong demand for the Company's diagnostic ultrasound and imaging products despite a reduction in revenue from government-backed loan programs and lack of daVinci sales versus prior periods. While revenue performance continues to reflect general uncertainty around healthcare reform and expenditure, which impacts demand and order flow for medical devices, the Company's second quarter revenue illustrates ongoing market opportunities and consistent demand for high-end medical products in China.

Gross profit for the Medical Products division was $6.7 million, compared to $4.7 million in the prior year period. Gross margin was 30.7% compared to 27.7 % in the prior year period, at the high end of historical averages. Selling, marketing, general and administrative expenses for the Medical Products division increased to $6.4 million from $6.2 million in the second quarter of the prior year. The division had an income from operations before foreign exchange of $306,000 for the three months ended September 30, 2011, compared with a loss of $1.5 million in the prior year period.

Lipson added, "In the second quarter, we witnessed strong demand for our imaging products, despite systemic headwinds relating to temporary regulatory uncertainty, which we believe could be alleviated in the coming months. Strict attention to optimizing our purchase behavior helped drive profitability this quarter, in tandem with our revenue performance. We continue to take a long-term view that the medical device market in China is extremely compelling."

First Half Fiscal 2011 Financial Results

During the first half of fiscal 2011, revenue increased 3.8% year over year to $86.7 million, compared to $83.5 million in the prior year. Revenue from the Healthcare Services division increased 11.9% to $48.1 million from $43.0 million in the first half of fiscal 2010. Revenue from the Medical Products division was $38.6 million, down 4.5% from $40.4 million in the prior year.

Income from operations remained flat at $6.6 million for the first half of fiscal 2011 as compared to the prior year period. Total operating costs and expenses for the fiscal year 2010 increased 4.0% to $79.9 million from $76.8 million in the prior year. This reflects $1.0 million of non-cash stock compensation expense compared to $1.5 million in the prior year period. Development, startup, and post-opening expenses in the Healthcare Services division were $1.1 million in the period compared to $642,000 in the prior year.

The Company recorded a $2.5 million provision for taxes, or an effective tax rate of 38.1%, in the first half of fiscal 2011, compared to a provision for taxes of $2.6 million, or an effective tax rate of 40.5%, for the prior year period.

In the first half of fiscal 2011, net income increased 7.9% to $4.1 million, or $0.26 per diluted share, from $3.8 million, or $0.24 per diluted share, in the prior year period. Non-cash stock compensation expense was $1.0 million during the first half of fiscal 2011 compared to $1.5 million in the prior year period.

Second Quarter Fiscal 2011 Conference Call

Management will host a conference call today at 8:00 am ET to discuss financial results.

To participate in the conference call, international callers should dial 1-760-666-3567 and domestic callers should dial 1-877-303-9231 approximately 10 minutes before the conference call is scheduled to begin.

The telephone replay will be available from the day of the call at (international) 1-706-645-9291 and (domestic) 1-800-642-1687, passcode 79429622.

This call is also being webcast and will be accessible at Chindex's website: http://ir.chindex.com/ev.... The event will be archived and available for replay through November 15, 2010.

About Chindex International, Inc.

Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,300 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites http://www.chindex.com and



Current liabilities:



Short-term debt, current portion of long-term debt and vendor financing

$-

$1,453

Accounts payable

16,825

13,979

Accrued expenses

10,876

14,022

Other current liabilities

4,739

3,826

Deferred revenue

2,664

2,549

Income taxes payable

2,034

2,218

Total current liabilities

37,138

38,047

Long-term debt, vendor financing and convertible debentures

22,894

22,593

Long-term accrued liabilities

126

84

Long-term deferred revenue

784

968

Long-term deferred tax liability

240

240

Total liabilities

61,182

61,932

Commitments and contingencies



Stockholders' equity:



Preferred stock, $.01 par value, 500,000 shares authorized, none issued

-

-

Common stock, $.01 par value, 28,200,000 shares authorized, including 3,200,000 designated Class B:



Common stock – 14,942,872 and 13,765,857 shares issued and outstanding at September 30, 2010 and March 31, 2010, respectively

149

138

Class B stock – 1,162,500 shares issued and outstanding at September 30, 2010 and March 31, 2010, respectively

12

12

Additional paid-in capital

114,645

100,269

Accumulated other comprehensive income

4,089

3,016

Retained earnings

9,549

5,476

Total stockholders' equity

128,444

108,911

Total liabilities and stockholders' equity

$189,626

$170,843




CHINDEX INTERNATIONAL, INC.

SEGMENT INFORMATION


The Company operates in two businesses: Healthcare Services and Medical Products. The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes, not including foreign exchange gains or losses.

(in thousands)

Healthcare Services

Medical Products

Total

For the three months ended September 30, 2010:




Sales and service revenue

$23,361

$21,813

$45,174

Gross Profit

n/a *

6,701

n/a

Gross Profit %

n/a *

31%

n/a

Income from operations before foreign exchange

$3,435

$306

$3,741

Foreign exchange gain

1,090

Income from operations



$4,831

Other (expense), net

(97)

Income before income taxes

$4,734

Assets as of September 30, 2010

$132,559

$57,067

$189,626









Healthcare Services

Medical Products

Total

For the three months ended September 30, 2009:


Sales and service revenue

$20,999

$17,120

$38,119

Gross Profit

n/a *

4,736

n/a

Gross Profit %

n/a *

28%

n/a

Income (loss) from operations before foreign exchange

$2,281

$(1,481)

$800

Foreign exchange gain

613

Income from operations



$1,413

Other income, net

134

Income before income taxes

$1,547

Assets as of March 31, 2010

$112,929

$57,914

$170,843











Healthcare Services

Medical Products

Total

For the six months ended September 30, 2010:




Sales and service revenue

$48,110

$38,552

$86,662

Gross Profit

n/a *

11,796

n/a

Gross Profit %

n/a *

31%

n/a

Income (loss) from operations before foreign exchange

$8,092

$(1,268)

$6,824

Foreign exchange loss

(98)

Income from operations



$6,726

Other (expense), net

(144)

Income before income taxes

$6,582

Assets as of September 30, 2010

$132,559

$57,067

$189,626









Healthcare Services

Medical Products

Total

For the six months ended September 30, 2009:




Sales and service revenue

$43,047

$40,404

$83,451

Gross Profit

n/a *

10,551

n/a

Gross Profit %

n/a *

26%

n/a

Income (loss) from operations before foreign exchange

$6,406

$(1,237)

$5,169

Foreign exchange gain

1,519

Income from operations



$6,688

Other (expense), net

(314)

Income before income taxes

$6,374

Assets as of March 31, 2010

$112,929

$57,914

$170,843

* Gross profit margins are not routinely calculated in the healthcare services industry.


]]> [Press Release] Chindex International, Inc. Reports First Quarter Fiscal 2011 Financial Results message_5400 09 Aug 2010 10:00:00 GMT http://chinasecurities.com/ir/ChindexInternational/messages/5400 BETHESDA, Md., Aug. 9 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq:CHDX - News), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced financial results for the first quarter of fiscal year 2011, which reflects the three month period ended June 30, 2010.

First Quarter 2011 Financial Results

Revenue in the first quarter of fiscal 2011 reflected continued growth in the Healthcare Services division offset by lower year over year revenue performance in the Medical Products division. Revenue from the Healthcare Services division increased 12.3% to $24.7 million from $22.0 million in the prior year period, and reflects growing inpatient and outpatient volume across the United Family Healthcare network. Revenue from the Medical Products division was down 28.3% to $16.7 million from $23.3 million in the prior year period. Total revenue decreased 8.4% to $41.5 million from $45.3 million in the first quarter of fiscal year 2010. The Company believes that the Class A review process in China, along with annual hospital budgeting cycles and a general uncertainty about healthcare reform and expenditure, continued to impact this division's performance in the first quarter of fiscal 2011.

Roberta Lipson, President and CEO of Chindex, commented, "Our strong revenue performance in the Healthcare Services division reflects continued demand for our services across the UFH network. We are focused on the further build out of our network of premium care hospitals and clinics, and remain optimistic about the future as we more than double capacity in Beijing, ramp up patient volume in Shanghai and Guangzhou, and make progress with new facilities in other growing Chinese cities. In our Medical Products division, the review process for Class A medical equipment continued to hinder daVinci sales, and purchasing behavior demonstrated the seasonally slower first quarter in line with annual budgeting processes. However, demand for high-value medical equipment remains strong in China and we are well-positioned to capitalize on the market for these products in the future."

Income from operations in the first quarter of fiscal 2011 was $1.9 million, compared to income from operations of $5.3 million in the same quarter last year. Total operating costs and expenses for the first quarter of fiscal 2011 were roughly flat at $40.0 million compared to $40.1 million in the prior year period, primarily reflecting a decrease in product sales costs offset by general and administration cost increases commensurate with revenue growth in the Healthcare Services division.

Operating expenses in the first quarter of fiscal 2011 include the impact of a $1.2 million unrealized foreign exchange loss, equivalent to a loss of $0.07 per diluted share, compared to a $906,000 unrealized foreign exchange gain, equivalent to a gain of $0.06 per diluted share, in the same quarter of the prior year. The unrealized exchange loss was incurred as a result of the substantial weakening of the Euro against the U.S. Dollar during the period which impacted the translated value of intercompany debt owed from the Company's German subsidiary to the U.S parent company. In the prior year the Company experienced the opposite circumstance.

Operating expenses also included $664,000 of non-cash stock compensation expense, equivalent to $0.04 per diluted share compared to $689,000, or $0.04 per diluted share in the prior year. Development, startup, and post-opening expenses in the Healthcare Services division were $388,000 or $0.02 per diluted share in the period compared to $329,000, or $0.02 per diluted share in the prior year.

Income from operations before foreign exchange in the first quarter of fiscal 2011 was $3.1 million, compared to $4.4 million in the prior year period.

The Company recorded a $1.0 million provision for taxes, an effective tax rate of 54.8%, in the first quarter of fiscal 2011 as compared to a provision for taxes of $1.6 million, or an effective tax rate of 32.6%, in the prior year period. The effective tax rate in the current period reflects increased losses in entities for which the Company cannot yet recognize a tax benefit.

Net income for the quarter ended June 30, 2010 was $836,000, or $0.06 per diluted share. This compares to net income of $3.3 million, or $0.20 per diluted share, in the prior year period.

Healthcare Services division business results:

In the first quarter of fiscal year 2011, revenue increased 12.3% to $24.7 million from $22.0 million in the prior year period. The increase reflects growing inpatient and outpatient volume across the Company's United Family Healthcare network.

In the first quarter of fiscal 2011, operating costs increased 12.3% to $20.1 million, a rate proportional to revenue growth and inclusive of additional staffing efforts. Income from operations before foreign exchange increased 14.6% to $4.7 million from $4.1 million in the prior year period.

Lipson continued, "Our growth this quarter reflects continued demand for services across our network. We are pleased to see more and more patients rely on us to treat increasingly acute indications in Beijing, while volumes in Shanghai and Guangzhou continued to validate that we are replicating the UFH brand in these newer locations. Additionally, the Beijing hospital expansion is on-track to more than double our capacity by calendar year-end."

Medical Products division business results:

For the first quarter of fiscal 2011, revenue was $16.7 million, down 28.3% from $23.3 million in the prior year period. Revenue performance reflects increased sales from women's health imaging and ultrasound products, offset by a reduction in revenue from government-backed loan programs and lack of daVinci sales versus the prior year period. Overall, revenue performance reflects the Class A review process and timing, which impacts daVinci order flow, along with anticipated hospital budgeting cycles and a general uncertainty around healthcare reform and expenditure, which impacts demand and order flow for medical devices.

Gross profit for the Medical Products division was $5.1 million, compared to $5.8 million in the prior year period. Gross margin was 30.4% compared to 25.0% in the prior year period, in line with historical averages and revenue mix. Selling, marketing, general and administrative expenses for the Medical Products division increased to $6.7 million from $5.6 million in the first quarter of the prior year. The division had a loss from operations before foreign exchange of $1.6 million for the three months ended June 30, 2010, compared with income from operations before foreign exchange of $243,000 for the three months ended June 30, 2009.

Lipson added, "We continue to believe order and shipment delays related to the regulatory review of high-value technologies is a temporary reality, which substantiates the overall demand in the market for these products. We take a long-term view that the medical device market in China is extremely compelling despite the current regulatory challenges, and we look forward to pursuing this large addressable market in the coming years."

First Quarter Fiscal 2011 Conference Call

Management will host a conference call today at 8:00 am ET to discuss financial results.

To participate in the conference call, international callers should dial 1-760-666-3567 and domestic callers should dial 1-877-303-9231 approximately 10 minutes before the conference call is scheduled to begin.

The telephone replay will be available from the day of the call at (international) 1-706-645-9291 and (domestic) 1-800-642-1687, passcode 79429622.

This call is also being webcast and will be accessible at Chindex's website: http://ir.chindex.com/ev... . The event will be archived and available for replay through August 16, 2010.

About Chindex International, Inc.

Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,300 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites http://www.chindex.com and
Current liabilities:
Short-term debt, current portion of long-term
debt and vendor financing $292 $1,453
Accounts payable 15,723 13,979
Accrued expenses 12,827 14,022
Other current liabilities 4,515 3,826
Deferred revenue 2,759 2,549
Income taxes payable 1,302 2,218
Total current liabilities 37,418 38,047
Long-term debt, vendor financing and
convertible debentures 22,704 22,593
Long-term accrued liabilities 72 84
Long-term deferred revenue 812 968
Long-term deferred tax liability 240 240
Total liabilities 61,246 61,932
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 500,000
shares authorized, none issued -- --
Common stock, $.01 par value, 28,200,000
shares authorized, including ,200,000
designated Class B:
Common stock - 13,765,611 and
13,765,857 shares issued and
outstanding at June 30, 2010
and March 31, 2010, respectively 138 138
Class B stock - 1,162,500 shares
issued and outstanding at June 30,
2010 and March 31, 2010, respectively 12 12
Additional paid-in capital 100,930 100,269
Accumulated other comprehensive income 3,290 3,016
Retained earnings 6,312 5,476
Total stockholders' equity 110,682 108,911
Total liabilities and
stockholders' equity $171,928 $170,843



CHINDEX INTERNATIONAL, INC.
SEGMENT INFORMATION

The Company operates in two businesses: Healthcare Services and Medical Products. The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes, not including foreign exchange gains or losses.



     (in thousands except share data)

                                            Healthcare   Medical
                                             Services    Products   Total
    For the three months ended June 30,
     2010:
    Sales and service revenue                 $24,749    $16,739   $41,488
    Gross Profit                                n/a *      5,095       n/a
    Gross Profit %                              n/a *        30%       n/a
    Income (loss) from operations before
     foreign  exchange                         $4,657    $(1,574)   $3,083
    Foreign exchange loss                                           (1,188)
    Income from operations                                          $1,895
    Other (expense), net                                               (47)
    Income before income taxes                                      $1,848

    Assets as of June 30, 2010               $116,919    $55,009  $171,928


                                            Healthcare   Medical
                                             Services    Products   Total
    For the three months ended June 30,
     2009:
    Sales and service revenue                 $22,048    $23,283   $45,331
    Gross Profit                                n/a *      5,814       n/a
    Gross Profit %                              n/a *        25%       n/a
    Income from operations before foreign
     exchange                                  $4,125       $243    $4,368
    Foreign exchange gain                                              906
    Income from operations                                          $5,274
    Other (expense), net                                              (448)
    Income before income taxes                                      $4,826

    Assets as of March 31, 2010              $112,929    $57,914  $170,843

    * Gross profit margins are not routinely calculated in the healthcare
      service industry.


    For more information, please contact:

     ICR, LLC
     Ashley M. Ammon
     Tel:   +1-646-277-1227
]]> [Press Release] Chindex International, Inc. Reports Fourth Quarter and Full Year Financials message_5337 14 Jun 2010 10:00:00 GMT http://chinasecurities.com/ir/ChindexInternational/messages/5337 BETHESDA, Md., June 14 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq:CHDX - News), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced financial results for the fourth quarter and fiscal year ended March 31, 2010.


    Financial Highlights:
    -- Revenue of $171.2 million in the fiscal year 2010
    -- Operating income up 76.6% year over year to $14.4 million in the fiscal
       year 2010
    -- Net income up 65% year over year to $8.2 million in the fiscal year
       2010, or $0.52 per diluted share, from $5.0 million, or $0.31 per
       diluted share in the prior year

Roberta Lipson, President and CEO of Chindex, commented, "We are pleased with our fiscal year 2010 financial results in which we demonstrated steady growth in Healthcare Services of 8% and increased profitability for the firm as a whole. We remain enthusiastic about the healthcare services and medical device market opportunity in China, particularly with the confluence we see in China right now, specifically economic development, government support for leading providers and consumer demand for premium care."

Fourth Quarter 2010 Financial Results

Revenue in the fourth quarter of fiscal year 2010 decreased 30.9% to $41.3 million from $59.7 million in the fourth quarter of fiscal year 2009, reflecting continued growth in Healthcare Services offset by revenue performance in the Medical Products division. Revenue from the Healthcare Services division increased 4.9% to $21.2 million from $20.2 million in the fourth quarter of fiscal year 2009, and reflected growing inpatient and outpatient volume across the network despite construction-related disruption at the Company's Beijing facility. Consistent with prior quarters, Chindex expects the impact of the expansion work to continue through the opening of the expanded facilities, currently planned for the fall of 2010. Revenue from the Medical Products division was down 49.1% to $20.1 million from $39.5 million in the prior year period. The Company believes that the Ministry of Health Class A review process and timing, along with a general uncertainty around healthcare reform and expenditure, undermined this division's performance in the fourth quarter of fiscal 2010.

Income from operations in the fourth quarter of fiscal year 2010 was $1.1 million, compared to income from operations of $3.9 million in the same quarter last year. Total operating costs and expenses for the fourth quarter of fiscal year 2010 decreased 28.1% to $40.1 million from $55.8 million in the prior year period, primarily reflecting the decrease of 52.2% in product sales costs to $14.6 million in the fourth quarter of 2010. Operating costs also included $236,000 of development and startup expenses for new clinics, equivalent to $0.01 per diluted share, and non-cash stock compensation expense of $853,000 or $0.05 per diluted share. In the prior year period, the Company's development and startup expense were $536,000, or $0.03 per diluted share, and non-cash stock compensation expense was $848,000, or $0.05 per diluted share.

The Company recorded a $791,000 provision for taxes, an effective tax rate of 60.6%, in the fourth quarter of fiscal year 2010 as compared to a provision for taxes of $615,000, or an effective tax rate of 15.3%, in the prior year period. The tax rate reflects losses in entities for which the Company cannot yet recognize a benefit.

Net income for the quarter ended March 31, 2010 was $515,000, or $0.04 per diluted share. This compares to net income of $3.4 million, or $0.22 per diluted share, in the prior year period.

Healthcare Services division business results:

In the fourth quarter of fiscal year 2010, revenue increased 4.9% to $21.2 million from $20.2 million in the prior year period. The increase reflects growing inpatient and outpatient volume across the Company's network offset by near-term disruption related to expansion construction in Beijing.

In the fourth quarter of fiscal year 2010, operating costs were flat on a year over year basis at $18.8 million, and income from operations before foreign exchange loss increased 75.4% to $2.4 million from $1.3 million in the prior year period.

Lipson continued, "Our growth this quarter was consistent with our expectations and reflects continued demand for services across our network, offset slightly by construction-related disruption at our Beijing facility, where we are more than doubling our capacity by calendar year-end. We moved several exciting projects forward this quarter including officially launching the New Hope Oncology Center, entering design phase for the new facility in Tianjin, as well as meeting further demand for our services in Shanghai and Guangzhou. Overall, we remain uniquely positioned as a leading premium provider in China's healthcare services space and we are looking forward to more progress in the fiscal year ahead."

Medical Products division business results:

For the fourth quarter of fiscal year 2010, revenue was $20.1 million, down 49.1% from $39.5 million in the prior year period. Revenue performance mainly reflects the Ministry of Health's Class A review process and timing, which impacts daVinci order flow, along with a general uncertainty around healthcare reform and expenditure, which impacts overall demand and order for medical devices.

Gross profit for the Medical Products division was $5.5 million, compared to $9.0 million in the prior year period. Gross margin was 28% compared to 23% in the prior year period, in line with historical averages and revenue mix. Selling, marketing, general and administrative expenses for the Medical Products division decreased to $5.9 million from $6.3 million in the fourth quarter of the prior year.

Revenue from the Medical Products division was $85.4 million in the fiscal year 2010, a decrease of 7.2% from $92.1 million in the prior year. Gross profit in the division was $23.4 million, which yielded a gross margin of 27%, compared to $23.1 million, which yielded a gross margin of 25%, in the fiscal year 2009. Selling, marketing, general and administrative expenses for the Medical Products division increased 5.2% to $23.7 million from $22.6 million in the prior year, reflecting the increased selling activity.

Lipson added, "Despite the temporary challenges in our Medical Products division, we believe the medical device market in China remains extremely compelling. We believe order and shipment delays related to the regulatory review of high-value technologies is a temporary reality which substantiates the overall demand in the market for these products. Additionally, we are delighted to announce today our strategic partnership with Fosun Pharmaceuticals, a transformative event for Chindex and for our Medical Products division in particular."

Full Year 2010 Financial Results

During the fiscal year 2010, revenue remained flat on a year over year basis at $171.2 million, compared to $171.4 million in the prior year. Revenue from the Healthcare Services division increased 8.1% to $85.8 million from $79.4 million in fiscal year 2009. Revenue from the Medical Products division was $85.4 million, down 7.2% from $92.1 million in the prior year.

Income from operations increased 76.6% to $14.4 million for the full year ended March 31, 2010, from $8.2 million in the prior year. Total operating costs and expenses for the fiscal year 2010 decreased 4.0% to $156.8 million from $163.3 million in the prior year.

The Company recorded a $6.1 million provision for taxes, or an effective tax rate of 42.6%, in the fiscal year 2010, compared to a provision for taxes of $2.7 million, or an effective tax rate of 35.1%, for the fiscal year 2009.

In the fiscal year 2010, net income increased 65.3% to $8.2 million, or $0.52 per diluted share, from $5.0 million, or $0.31 per diluted share, in the prior year. Non-cash stock compensation expense was $3.3 million during the fiscal year 2010 compared to $2.9 million in the prior year.

Fourth Quarter Fiscal 2010 Conference Call

Management will host a conference call today at 8:00 am ET to discuss financial results.

To participate in the conference call, international callers should dial 1-760-666-3567 begin_of_the_skype_highlighting 1-760-666-3567 end_of_the_skype_highlighting and domestic callers should dial 1-877-303-9231 begin_of_the_skype_highlighting 1-877-303-9231 end_of_the_skype_highlighting approximately 10 minutes before the conference call is scheduled to begin.

The telephone replay will be available from the day of the call at (international) 1-706-645-9291 begin_of_the_skype_highlighting 1-706-645-9291 end_of_the_skype_highlighting and (domestic) 1-800-642-1687 begin_of_the_skype_highlighting 1-800-642-1687 end_of_the_skype_highlighting, passcode 79429622.

This call is also being webcast and will be accessible at Chindex's website: http://ir.chindex.com/ev... . The event will be archived and available for replay through June 28, 2010.

About Chindex International, Inc.

Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,300 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites http://www.chindex.com and
Current liabilities:
Short-term debt, current portion of
long-term debt and vendor financing $1,453 $1,631
Current portion of capitalized leases -- 22
Accounts payable 13,979 12,259
Accrued expenses 14,022 21,141
Other current liabilities 3,826 3,614
Deferred revenue 2,549 1,539
Income taxes payable 2,218 1,568
Total current liabilities 38,047 41,774
Long-term debt, vendor financing and
convertible debentures 22,593 23,709
Long-term accrued liabilities 84 --
Long-term deferred revenue 968 595
Long-term deferred tax liability 240 119
Total liabilities 61,932 66,197
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value,
500,000 shares authorized, none
issued -- --
Common stock, $.01 par value,
28,200,000 shares authorized,
including 3,200,000 designated
Class B:
Common stock - 13,765,857 and
13,452,007 shares issued and
outstanding at March 31, 2010 and
March 31, 2009, respectively 138 135
Class B stock - 1,162,500 shares
issued and outstanding at March 31,
2010 and March 31, 2009,
respectively 12 12
Additional paid-in capital 100,269 95,808
Accumulated other comprehensive
income 3,016 3,072
Retained earnings (accumulated
deficit) 5,476 (2,587)
Total stockholders' equity 108,911 96,440
Total liabilities and stockholders'
equity $170,843 $162,637




CHINDEX INTERNATIONAL, INC.
SEGMENT INFORMATION

The Company operates in two businesses: Healthcare Services and Medical
Products. The Company evaluates performance and allocates resources
based on profit or loss from operations before income taxes, not
including foreign exchange gains or losses.

(in thousands except share data)

Healthcare Medical
Services Products Total
For the three months ended March 31,
2010:
Sales and service revenue $21,168 $20,088 $41,256
Gross Profit n/a * 5,535 n/a
Gross Profit % n/a * 28% n/a
Income (loss) from operations before
foreign exchange $2,351 $(393) $1,958
Foreign exchange (loss) (825)
Income from operations $1,133
Other income, net 173
Income before income taxes $1,306
As of March 31, 2010:
Assets $112,929 $57,914 $170,843


Healthcare Medical
Services Products Total
For the three months ended March 31,
2009:
Sales and service revenue $20,186 $39,478 $59,664
Gross Profit n/a * 9,027 n/a
Gross Profit % n/a * 23% n/a
Income from operations before foreign
exchange $1,340 $2,693 $4,033
Foreign exchange (loss) (172)
Income from operations $3,861
Other income, net 171
Income before income taxes $4,032
As of March 31, 2009:
Assets $94,675 $67,962 $162,637

Healthcare Medical
Services Products Total
For the twelve months ended March 31,
2010:
Sales and service revenue $85,778 $85,413 $171,191
Gross Profit n/a * 23,354 n/a
Gross Profit % n/a * 27% n/a
Income (loss) from operations before
foreign exchange $14,393 $(366) $14,027
Foreign exchange gain 385
Income from operations $14,412
Other (expense), net (112)
Income before income taxes $14,300
As of March 31, 2010:
Assets $112,929 $57,914 $170,843


Healthcare Medical
Services Products Total
For the twelve months ended March 31,
2009:
Sales and service revenue $79,357 $92,085 $171,442
Gross Profit n/a * 23,058 n/a
Gross Profit % n/a * 25% n/a
Income from operations before foreign
exchange $7,309 $508 $7,817
Foreign exchange gain 342
Income from operations $8,159
Other (expense), net (508)
Income before income taxes $7,651
As of March 31, 2009:
Assets $94,675 $67,962 $162,637]]> [Press Release] Chindex International, Inc. Reports Third Quarter Results message_4641 08 Feb 2010 11:00:00 GMT http://chinasecurities.com/ir/ChindexInternational/messages/4641

BETHESDA, Md., Feb. 8 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced financial results for the third quarter and first nine months of fiscal year 2010.

    Financial Highlights:
    -- Revenue in the third quarter of fiscal year 2010 increased 12% year
       over year to $46.5 million;
    -- Net income for the third quarter of fiscal 2010 increased to $3.9
       million, or $0.24 per diluted share, from $846,000, or $0.05 per
       diluted share in the prior year period;
    -- The Company received a refund of $3.3 million for business tax paid
       since January 1, 2009 in the Healthcare Services division, equivalent
       to approximately $0.15 per diluted share;
    -- Revenue in the first nine months of 2009 increased 16.2% year over year
       to $129.9 million;
    -- Net income for the first nine months of 2009 increased to $7.7 million,
       or $0.48 per diluted share, from $1.5 million, or $0.10 per diluted
       share in the prior year period.

Roberta Lipson, President and CEO of Chindex, commented, "We are pleased with our profitability and year to date performance which reflect substantial improvements over last year. In the Healthcare Services division we are in a development cycle with operations in the Beijing market experiencing capacity limitations as we build out the expansion facilities. At the same time, operations in the Shanghai and Guangzhou markets continue along expected growth trajectories. The Medical Products division is always subject to quarterly fluctuations, and although we are seeing significant improvements over last year, we are experiencing regulatory delays on high-value medical equipment purchases. Nevertheless, there continues to be significant excitement in the marketplace for our products, particularly for the daVinci surgical robot and the new S/SC 2000 ultrasound platform. As we enter the fourth quarter, and look forward into our next fiscal year, we remain extremely well-positioned to capitalize on China's premium-quality healthcare services market, continued economic vibrancy and opportunities created by healthcare reform."

Revenue in the third quarter of fiscal year 2010 increased 12% to $46.5 million from $41.6 million in the third quarter of fiscal year 2009. Revenue from the Healthcare Services division increased 5% to $21.6 million from$20.5 million in the third quarter of fiscal year 2009, and reflected growing inpatient and outpatient volume offset by disruption due to construction of the expanded facility in Beijing. The Company expects the negative impact of the expansion work to continue through the opening of the expanded facilities, currently planned for the fall of 2010. Revenue from the Medical Products division increased 18% to $24.9 million from $21.1 million in the prior year period, reflecting the increase in sales of women's health imaging products and the delivery of two robotic surgical systems. During this quarter, the Company also recorded revenues of approximately $3.2 million under its current KfW Development Bank contracts.

During the quarter, the Company recorded income from operations of $6.6 million, compared to income from operations of $1.9 million in the same quarter last year. Income from operations includes the benefit of a $3.3 million business tax refund related to the Healthcare Services division. This tax refund is equivalent to approximately $0.15 per diluted share. Total operating costs and expenses for the third quarter of fiscal year 2010 were flat on a year over year basis and included $269,000 of development and startup expenses for new clinics, equivalent to $0.02 per diluted share, and non-cash stock compensation expense of $888,000, or $0.05per diluted share. In the prior period, the Company's development and startup expense were $662,000, or $0.04per diluted share, and non-cash stock compensation expense was $810,000, or $0.05 per diluted share.

The Company recorded a $2.7 million provision for taxes, or an effective tax rate of 41.1%, in the third quarter of fiscal year 2010 as compared to a provision for taxes of $658,000, or an effective tax rate of 43.7%, in the prior year period. The tax rate reflects losses in entities for which the Company cannot yet recognize a benefit.

Net income for the quarter ended December 31, 2009 was $3.9 million, or $0.24 per diluted share. Excluding the tax refund explained above, net income for the third quarter of fiscal year 2010 would be $1,497,000, or$0.09 per diluted share. This compares to net income of $846,000, or $0.05 per diluted share, in the prior year period.

Healthcare Services division business results:

For the third quarter of fiscal year 2010, revenue increased 5% to $21.6 million from $20.5 million for the prior year quarter. The increase reflected growing inpatient and outpatient volume offset by disruption due to construction of the expanded facility in Beijing.

Excluding the $3.3 million tax benefit discussed above, operating costs increased by 5% to $19.3 million, and income from operations before foreign exchange gains increased to $5.6 million from $2.1 million in the prior year period.

Lipson continued, "We were pleased to see our revenue increase sequentially and on a year over year basis despite the temporary disruption at our BJU facility, which should more than double our capacity by calendar year-end. We were also particularly excited to receive a $3.3 million business tax rebate and receive a business tax exemption going forward. We believe this treatment from authorities in the for-profit hospital sector, is evidence that healthcare reform efforts in China will continue to drive growth throughout the sector and further enhance our position as the leading, private sector provider in the premium-care market."

Medical Products division business results:

For the third quarter of fiscal year 2010, revenue increased 18% to $24.9 million from $21.1 million in the prior year quarter. Revenue performance mainly reflected increases in sales of women's health imaging products and delivery of two robotic surgical systems.

Revenue performance year to date also reflects continued delays in the order cycle for high value capital medical equipment, particularly for robotic surgical systems, resulting from the Chinese government's review of these technologies as well as the overall timing of the tender process in China. Sales excluding daVinci were lower than the prior year period, reflecting the introduction of a new generation of technology in diagnostic ultrasound which replaced the previous market leading product. During this quarter, the Company also recorded revenues of approximately $3.2 million under its current KfW Development Bank contracts.

Gross profit for the Medical Products division increased to $7.3 million from $5.6 million in the prior year's third quarter, representing an increase in gross profit margin to 29% from 26% in the year over year period. The variance in gross profit margin is in line with historical averages.

Lipson concluded, "The government's review of high value technologies used in public hospitals is a routine process impacting new, big ticket medical products. We believe that the review itself substantiates the continued demand we see for premium medical technology in China, and bodes well for future sales across our portfolio despite causing disruptions to daVinci sales this quarter."

Fiscal 2010 Third Quarter Conference Call

Management will host a conference call today at 8:00 am ET to discuss financial results.

To participate in the conference call, international callers should dial 1-719-325-4757 and domestic callers should dial 1-877-874-1568 approximately 10 minutes before the conference call is scheduled to begin.

The telephone replay will be available on the day of the call at (international) 1-719-457-0820 and (domestic) 1-888-203-1112 and continue to be available through February 22, 2010.

This call is also being webcast and will be accessible at Chindex's website http://ir.chindex.com/ev... . The event will be archived and available for replay through February 22, 2010.

About Chindex International, Inc.

Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in the Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals inChina utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,300 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services toGreater China's professional communities. Further company information may be found at the Company's websites http://www.chindex.com and

The Company operates in two businesses: Healthcare Services and Medical Products. The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes, not including foreign exchange gains or losses. The following segment information has been provided per Statement of Financial Accounting Standards No. 131, "Disclosures about Segments of an Enterprise and Related Information:" (in thousands except percentages)

                                        Healthcare     Medical
                                         Services     Products     Total
    For the three months ended
     December 31, 2009:
    Sales and service revenue             $21,563      $24,921    $46,484
    Gross Profit                            n/a *        7,269        n/a
    Gross Profit %                          n/a *          29%        n/a
    Income from operations before
     foreign exchange                      $5,637       $1,265     $6,902
    Foreign exchange loss                                            (309)
    Income from operations                                         $6,593
    Other income, net                                                  27
    Income before income taxes                                     $6,620
    Assets as of December 31, 2009       $106,242      $63,037   $169,279


                                       Healthcare      Medical
                                        Services      Products     Total
    For the three months ended
     December 31, 2008:
    Sales and service revenue             $20,530      $21,070    $41,600
    Gross Profit                            n/a *        5,577        n/a
    Gross Profit %                          n/a *          26%        n/a
    Income (loss) from operations
     before foreign exchange               $2,142        $(630)    $1,512
    Foreign exchange gain                                             385
    Income from operations                                         $1,897
    Other (expense), net                                             (393)
    Income before income taxes                                     $1,504
    Assets as of March 31, 2009           $94,675      $67,962   $162,637


                                        Healthcare     Medical
                                         Services     Products     Total
    For the nine months ended
     December 31, 2009:
    Sales and service revenue             $64,610      $65,324   $129,934
    Gross Profit                            n/a *       17,818        n/a
    Gross Profit %                          n/a *          27%        n/a
    Income from operations before
     foreign exchange                     $12,043          $25    $12,068
    Foreign exchange gain                                           1,210
    Income from operations                                        $13,278
    Other (expense), net                                             (285)
    Income before income taxes                                    $12,993
    Assets as of December 31, 2009       $106,242      $63,037   $169,279


                                        Healthcare     Medical
                                         Services     Products     Total
    For the nine months ended
     December 31, 2008:
    Sales and service revenue             $59,171      $52,607   $111,778
    Gross Profit                            n/a *       14,031        n/a
    Gross Profit %                          n/a *          27%        n/a
    Income (loss) from operations
     before foreign exchange               $5,970      $(2,185)    $3,785
    Foreign exchange gain                                             513
    Income from operations                                         $4,298
    Other (expense), net                                             (679)
    Income before income taxes                                     $3,619
    Assets as of March 31, 2009           $94,675      $67,962   $162,637

    * Gross profit margins are not routinely calculated in the healthcare
      service industry.


    For more information, please contact:

    Integrated Corporate Relations
     Ashley M. Ammon
     Tel:   +1-646-277-1227

]]> [Press Release] Chindex International to Present at the J.P. Morgan Healthcare Conference in Jan message_4363 05 Jan 2010 21:30:00 GMT http://chinasecurities.com/ir/ChindexInternational/messages/4363 BETHESDA, Md., Jan. 5 /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex") (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced that the Company will present at the 28th Annual J.P. Morgan Healthcare Conference, to be held January 11-14, 2010 at the Westin St. Francis Hotel in San Francisco, CA.

Management is currently scheduled to present at 1:00 pm PT on Thursday, January 14, 2010 and meet with institutional investors throughout the day. A webcast of the presentation will be available via Chindex's website at http://ir.chindex.com/ev... .

Additionally, the Company will present at the Jefferies 2010 Global Healthcare Services Conference, to be held January 25-27, 2010 at the Mandarin Oriental Hotel in New York City. Management is scheduled to present at 7:30 am ET on Tuesday, January 26, 2010 and meet with institutional investors throughout the day. A webcast of the presentation will be available via Chindex's website at http://ir.chindex.com/ev... .

For more details, please contact your respective institutional sales representative.

About Chindex International, Inc.

Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in the Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,300 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites http://www.chindex.com and http://www.unitedfamilyh... .

    For more information, please contact:

     Integrated Corporate Relations
     Ashley M. Ammon
     Tel: +1-646-277-1200
]]> [Press Release] Chindex International to Present at Piper Jaffray Health Care Conference message_4123 24 Nov 2009 21:01:00 GMT http://chinasecurities.com/ir/ChindexInternational/messages/4123 BETHESDA, Md., Nov. 24 /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex") (Nasdaq: CHDX - News), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced that the Company will attend the 21st Annual Piper Jaffray "Unplugged" Health Care Conference, to be held December 1 - 2, 2009, at the New York Palace Hotel.

Management is currently scheduled to present at 11:30 am ET on Tuesday, December 1, 2009, and hold one-on-one meetings throughout the day. A webcast of the presentation will be available via Chindex's website at http://ir.chindex.com/ev... .

For more details on the conference, please contact your Piper Jaffray institutional sales representative.

About Chindex International, Inc.

Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in the Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,300 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites http://www.chindex.com and http://www.unitedfamilyh... .

    For further information, please contact:

    Integrated Corporate Relations
     Ashley M. Ammon
     Tel: +1-646-277-1200
]]> [Press Release] Chindex International, Inc. to Report Second Quarter Fiscal 2010 Financial Resul message_3700 26 Oct 2009 10:30:00 GMT http://chinasecurities.com/ir/ChindexInternational/messages/3700 BETHESDA, Md., Oct. 26 /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex") (Nasdaq: CHDX - News), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced that it plans to release second quarter fiscal 2010 financial results on Monday, November 9, 2009, before the market opens. Management will host a conference call at 8:00 am ET on November 9, 2009 to discuss financial results.

To participate in the conference call, international callers dial 1-913-312-1510 and domestic callers dial 1-888-724-9518 approximately 10 minutes before the conference call is scheduled to begin.

The telephone replay will be available from the day of the call until November 23, 2009 by dialing (international) 1-719-457-0820 and (domestic) 1-888-203-1112, passcode 9542409.

A webcast will be accessible via Chindex's website at http://ir.chindex.com/ev... .

About Chindex International, Inc.

Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in the Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,300 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites http://www.chindex.com and http://www.unitedfamilyh... .

    For more information, please contact:

     Integrated Corporate Relations
     Ashley M. Ammon
     Tel: +1-646-277-1200
]]> [Press Release] Chindex International Announces September Investor Conferences Participation message_3216 02 Sep 2009 20:01:00 GMT http://chinasecurities.com/ir/ChindexInternational/messages/3216 BETHESDA, Md., Sept. 2 /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex") (Nasdaq: CHDX - News), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced its participation in the following conferences:

    -- Morgan Stanley Healthcare Corporate Day, to be held September 11, 2009
       in Boston, MA. Management will meet with institutional investors
       throughout the day.

    -- Susquehanna Financial Group Third Annual Beijing Management Summit, to
       be held September 16-17, 2009 in Beijing, China. Roberta Lipson, Chief
       Executive Officer of Chindex International, will speak on a panel
       discussion entitled, "China Medical Device/Healthcare Services Panel,"
       scheduled from 9:10-10:15am Beijing Time on September 17, 2009. In
       addition, management will also present at 10:20am Beijing Time on
       September 17, 2009 and meet with institutional investors throughout
       both days.

    -- Maxim Group Growth Conference, to be held September 29, 2009 at the
       Grand Hyatt in New York City. Management will present at 10:30am ET on
       September 29, 2009 and meet with institutional investors throughout the
       day. A live webcast will be available via the following link:
       http://www.unitedfamilyh... .


    For more information, please contact:

    Integrated Corporate Relations
     Ashley M. Ammon
     Tel: +1-203-682-8200
]]>
      
    
    
      [Press Release] Chindex International, Inc. Announces New CDC Contract
      message_3045
      19 Aug 2009 20:01:00 GMT
      http://chinasecurities.com/ir/ChindexInternational/messages/3045
      
        BETHESDA, Md., Aug. 19 /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex") (Nasdaq: CHDX - News), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced that it has entered into a contract to supply EUR5 million in laboratory and hospital products to Centers for Disease Control in China's Qinghai Province. The purchase is being financed by the KfW Development Bank of Germany under a government to government program. The signing ceremony was held today in Beijing and the contract is expected to ship during the current fiscal year.



Roberta Lipson, Chindex President and CEO, commented, "Chindex continues to be a key supplier under the KfW program's Centers for Disease Control efforts in China. We are pleased to once again be implementing another KfW program, utilizing the expertise that we have developed in government-sponsored loan projects, to provide an increasingly diversified and robust array of medical and laboratory products to China's healthcare communities."


About Chindex International, Inc.


Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-eight years of experience, approximately 1,300 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, http://www.chindex.com and http://www.unitedfamilyh... .


Safe Harbor Statement


Statements made in this press release relating to plans, strategies, objectives, economic performance and trends and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the factors set forth under the heading "Risk Factors" in our annual report on Form 10-K for the year ended March 31, 2009, updates and additions to those "Risk Factors" in our interim reports on Form 10-Q, Forms 8-K and in other documents filed by us with the Securities and Exchange Commission from time to time. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue" or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We have no obligation to update these forward-looking statements.


    For more information, please contact:

    Integrated Corporate Relations
     Ashley M. Ammon
     Tel: +1-203-682-8200
]]>
      
    
    
      [Press Release] Chindex posts 4Q profit on medical-product sales
      message_2398
      11 Jun 2009 05:25:00 GMT
      http://chinasecurities.com/ir/ChindexInternational/messages/2398
      
        Chindex International says medical-product revenue more than doubled in fiscal 4th quarter


BETHESDA, Md. (AP) -- Chindex International Inc., which sells medical products in China, said Thursday it turned a profit in the fiscal fourth quarter as hospital revenues and sales of medical devices climbed.


Chindex said it earned $3.4 million, or 22 cents per share, in the three months ending March 31. The company had lost $2.7 million, or 20 cents per share, last year. Revenue jumped 72 percent, to $59.7 million from $34.6 million as product sales more than doubled.


The Bethesda, Md., company said medical-products revenue rose to $39.5 million from $17.5 million due to gains from government-backed loan programs, increased inpatient and outpatient revenues from its hospital unit, and greater sales of devices like the da Vinci robotic-surgery system.


Healthcare-services revenue edged up to $20.2 million from $17.5 million.


For the fiscal year, Chindex's profit grew 36 percent, to $5 million, or 31 cents per share, from $3.7 million, or 27 cents per share. Sales grew 32 percent, to $171.4 million from $130 million.
]]>
      
    
    
      [Press Release] Chindex International, Inc. to Report Fourth Quarter and Full Year Fiscal 2009
      message_2347
      01 Jun 2009 20:17:00 GMT
      http://chinasecurities.com/ir/ChindexInternational/messages/2347
      
        BETHESDA, Md., June 1 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of western healthcare products and services in the People's Republic of China, today announced that it plans to release fourth quarter and full year fiscal 2009 financial results on Thursday, June 11, 2009, before the market opens. Management will host a conference call at 8:00 am ET that day to discuss financial results.


To participate in the conference call, international callers dial 1-719-325-4805 and domestic callers dial 1-877-852-6581 approximately 10 minutes before the conference call is scheduled to begin.


The telephone replay will be available on the day of the call at (international) 1-719-457-0820 and (domestic) 1-888-203-1112; passcode 4974069 and continue to be available through June 25, 2009.


This call is also being webcast and will be accessible at Chindex's website http://ir.chindex.com/ev... .


About Chindex International, Inc.


Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in the Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,200 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, http://www.chindex.com and http://www.unitedfamilyh... .


    For more information, please contact:

    Integrated Corporate Relations
     Ashley M. Ammon
     Tel: +1-203-682-8200
]]>
      
    
    
      [Press Release] Chindex International, Inc. Announces May Conference Participation
      message_1877
      05 May 2009 05:00:00 GMT
      http://chinasecurities.com/ir/ChindexInternational/messages/1877
      
        BETHESDA, Md., May 5 /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex" or the "Company") (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced that the Company is scheduled to participate in the Oppenheimer 3rd Annual China Dragon Call Conference, held May 19-21, 2009, at 300 Madison Avenue in New York City. Management is scheduled to present at 3:35 pm ET on Thursday, May 21, 2009, and meet with institutional investors the same day.


The Company will also participate in the Credit Suisse China Healthcare Tour, held the week of May 18, 2009, in China.


For more details on these events, please contact your respective sales representative.


About Chindex International, Inc.


Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,200 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, http://www.chindex.com and http://www.unitedfamilyhospitals.com .


    For more information, please contact:

    Integrated Corporate Relations
     Ashley M. Ammon
     Tel: +1-203-682-8200
]]>
      
    
    
      [Press Release] ACM Global Lab Announces Partnership with Chindex's United Family Hospitals
      message_1413
      01 Apr 2009 05:00:00 GMT
      http://chinasecurities.com/ir/ChindexInternational/messages/1413
      
        ROCHESTER, N.Y., YORK, England and BETHESDA, Md., April 1 /PRNewswire-Asia/ -- ACM Global Central Laboratory, the laboratory that continually defines the client-service standard with its inherently flexible approach, and Chindex International, Inc. (Nasdaq: CHDX - News), today announced a partnership to provide central lab services in China at United Family Hospitals, Beijing (UFH).  UFH is a CAP-certified facility owned by Chindex International, Inc.


ACM Global Central Laboratory conducted a harmonization program in China, and chose to work with Chindex in order to ensure the same degree of global standards that clients enjoy from the Americas, Europe, India and Australasia. Offering on-the-ground central lab capabilities in China is a significant milestone in the organization's history.


"Given the challenges of exporting whole blood from Mainland China coupled with the demand for conducting trials in China, we recognized the importance of establishing services locally," said Elena Logan, Vice President, ACM Global Central Laboratory. "We also refuse to compromise on quality and working with Chindex helps us maintain our rigorous service standards in an exciting developing market. I'm honored to be able to work with the UFH team led by US trained pathologist, Dr. Sun Fei, who will oversee the clinical trial efforts at UFH."


"As the only Western-founded hospital lab in Beijing, and the only JCI accredited hospital in China with CAP accreditation, UFH is well-poised to provide unparalleled central lab services.  Working with a global leader like ACM acknowledges our unique competitive position as well as our dedication to high standards of care.  We also look forward to providing additional diagnostic testing to the local community through this partnership," said Roberta Lipson, CEO of Chindex.


ACM's global operations extend to more than 60 countries, including the Americas, Europe, including Eastern Europe and Russia, Australia, Asia, Israel, South Africa and India - with all tests conducted and managed from central lab facilities with seamless data management providing a single database. Combining comprehensive safety, efficacy and pathology testing from a single lab ensures clients receive consistent, analyzable test results with faster and cleaner reporting.


"China is an exciting and rapidly growing market for clinical trials and our central lab capabilities there represent an important development for the company," said Tracy Hendershott, Director, Global Operations "Partnering with a qualified lab in China gives us the ideal mix of global standardization combined with local expertise to deliver the best possible service to our clients."


About ACM Global Central Laboratory


ACM Global Central Laboratory has an inherently flexible approach and a focus on precision to keep clinical research studies on schedule.  The organization sets itself apart by its single focus on global central lab services.  ACM is defining the industry standard by continually developing client-focused processes and services.  ACM's global operations extend to more than 60 countries and offer a broad and customized menu of safety and specialty services for clinical trials.  The organization performs 13 million tests each year, featuring more than 1,500 individual tests spanning all medical disciplines, including Pathology, Microbiology and Pharmacogenomics. For more information, visit http://www.acmgloballab.com .


About Chindex International, Inc. and United Family Hospitals


Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in the Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,200 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, http://www.chindex.com and http://www.unitedfamilyhospitals.com .


Safe Harbor Statement


Statements made in this press release relating to plans, strategies, objectives, economic performance and trends and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the factors set forth under the heading "Risk Factors" in our annual report on Form 10-K for the year ended March 31, 2008, updates and additions to those "Risk Factors" in our interim reports on Form 10-Q, Forms 8-K and in other documents filed by us with the Securities and Exchange Commission from time to time. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential" or "continue" or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We have no obligation to update these forward- looking statements.


    For further information, please contact:

    Integrated Corporate Relations
     Ashley M. Ammon
     Tel: +1-203-682-8200
]]>
      
    
    
      [Press Release] Chindex to Present at Credit Suisse 12 Asian Investment Conference in Hong Kong
      message_798
      12 Mar 2009 15:01:00 GMT
      http://chinasecurities.com/ir/ChindexInternational/messages/798
      
        BETHESDA, Md., March 12 /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex" or the "Company") (Nasdaq: CHDX - News), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced that the Company will attend the Credit Suisse 12th Asian Investment Conference (the "Conference"), to be held at the Shangri-La Hotel in Hong Kong from March 24 - 27, 2009.






Roberta Lipson, Chief Executive Officer of Chindex International, will speak on a panel discussion entitled, "China Healthcare Stimulus and Reform: CAPEX vs. Consumption," scheduled from 4:30-6:00 pm on Tuesday, March 24. Additionally, management is scheduled to give an investor presentation and hold one-on-one meetings with investors.


For more details on the Conference, please contact your Credit Suisse sales representative.


About Chindex International, Inc.


Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong.  Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in Beijing, Shanghai, Guangzhou and Wuxi.  The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively.  It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank.  With twenty-seven years of experience, approximately 1,200 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities.  Further company information may be found at the Company's websites, http://www.chindex.com and http://www.unitedfamilyhospitals.com .


    For more information, please contact:

     Integrated Corporate Relations
     Ashley M. Ammon
     Tel:   +1-203-682-8200
]]>
      
    
    
      [Press Release] Chindex International, Inc. to Participate in the Piper Jaffray & ChinaVenture
      message_787
      04 Mar 2009 15:01:00 GMT
      http://chinasecurities.com/ir/ChindexInternational/messages/787
      
        Chindex International, Inc. to Participate in the Piper Jaffray & ChinaVenture Investment Conference 2009

BETHESDA, Md., March 4 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced that the Company will attend the Piper Jaffray & ChinaVenture Investment Conference 2009, to be held at the Grand Hyatt in Shanghai on March 16 and 17. The Company will conduct meetings with institutional investors and will host a group investor tour of the United Family Hospital in Shanghai.


Additionally, Roberta Lipson, Chief Executive Officer of Chindex International, is scheduled to speak on a panel discussion entitled, "Anticipating Impact from the Economy and Healthcare Spending," on March 17.


For more details on the conference, please contact your Piper Jaffray sales representative or visit http://events.chinaventure.com.cn/sh...  .


About Chindex International, Inc.


Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,200 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, http://www.chindex.com and http://www.unitedfamilyhospitals.com .


    For more information, please contact:

     Integrated Corporate Relations
     Ashley M. Ammon
     Tel: +1-203-682-8200
]]>
      
    
    
      [Press Release] Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results
      message_788
      09 Feb 2009 05:00:00 GMT
      http://chinasecurities.com/ir/ChindexInternational/messages/788
      
        BETHESDA, Md., Feb. 9 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced financial results for the third quarter of fiscal year 2009.


Revenue in the third quarter of fiscal year 2009 increased 16% to $41.6 million from $36.0 million in the third quarter of fiscal year 2008. Revenue from the healthcare services division increased 16% to $20.5 million from $17.7 million in the third quarter of fiscal year 2008, and revenue from the medical products division increased 15% to $21.1 million from $18.3 million in the prior year period. Revenue performance reflects growth in inpatient and outpatient revenues in the hospital division and increasing demand for medical equipment products and services, partially offset by delays in openings of new clinics in Shanghai and Guangzhou as well as the delay until the fourth quarter in the recognition of revenue for certain medical equipment shipped as part of a development bank equipment supply contract.


During the quarter, the Company recorded income from operations of $1.9 million, compared to income from operations of $3.9 million in the same quarter last year. Total operating costs and expenses for the third quarter of fiscal year 2009 increased 24% to $39.7 million as compared with $32.1 million in the prior period. Increased operating costs reflect $662,000 of development and startup expenses for new clinics, as well as costs for the renewal of multi-year physician contracts, additional medical personnel in our Beijing and Shanghai hospitals, increased direct patient care costs and increased medical products selling activities.


Roberta Lipson, President and CEO of Chindex, commented, "We made substantial progress this quarter in our KfW and U.S. Export-Import Bank contracts and remain confident that we can complete deliveries of the remaining $18.4 million by the end of this fiscal year. We are also keeping a close eye on the healthcare reform in China and continue to believe that Chindex is well positioned to benefit from these efforts over the long term."


As previously disclosed, in October 2008, the Company redeemed variable- return CDs and reinvested the funds in traditional deposits with guaranteed returns, given the unfavorable economic outlook. This change was made to minimize the effect of the significant disruptions in the world financial and credit markets. In connection with this, the Company recognized a pretax expense of $653,000, or $0.03 per diluted share, reflecting the early redemption of the CDs and related write offs and tax benefit.


The Company recorded a $658,000 provision for taxes, or an effective tax rate of 43.7%, in the three months ended December 31, 2008 as compared to a provision for taxes of $76,000, or an effective tax rate of 1.9%, for the three months ended December 31, 2007. The current period tax expense includes the negative effect of losses in entities for which Chindex cannot recognize a benefit in accordance with SFAS 109, "Accounting for Income Taxes." The Company's effective tax rate was low in the prior year period due to an increase in its net deferred tax assets resulting from an increase in the projected profitability in future periods of entities in the U.S. and China.


Net income for the quarter ended December 31, 2008 was $846,000, or $0.05 per diluted share. This compares to net income of $3.9 million, or $0.28 per diluted share, for the quarter ended December 31, 2007.


Net income in the third quarter of fiscal 2009 includes $662,000 of expenses, or $0.03 per diluted share, related to development expenses for expansion of the United Family Healthcare network, as well as $653,000, or $0.03 per diluted share, in connection with variable-return CDs described above.


Medical Products division business results:


For the third quarter of fiscal year 2009, revenue increased 15% to $21.1 million from $18.3 million in the prior year quarter. As of December 31, 2008, deferred revenue increased to $3.8 million, which mainly reflects $2.4 million of deferred revenue recorded in the fiscal third quarter of 2009 related to the execution of one of the KfW Development Bank contracts.


Gross profit for the Medical Products division increased to $5.6 million from $5.2 million in the prior year's third quarter, representing a decrease in gross profit margin to 26% from 28% in the year over year period. A 2% variance in gross profit margin is in line with historical averages.


Selling, marketing, general and administrative expenses for the Medical Products division increased 24% to $6.2 million from $5.0 million in the third quarter of the prior year. Increased expenses during the period were a result of increased selling activity in advance of expected sales increases.


Lipson added, "Our Medical Products division continues to be well positioned to capitalize on the increased need for high end, high margin medical products in China. We approach this division with a long-term view. While our costs did not increase substantially in this division versus the second quarter of fiscal 2009, results were impacted by timing of revenue recognition."


Healthcare Services division business results:


For the third quarter of fiscal year 2009, revenue increased 16% to $20.5 million from $17.7 million for the prior year quarter. The increase in revenue is attributable to growth in both inpatient and outpatient revenues provided in the Beijing and Shanghai markets, but which was less than expected.


During the period, operating costs increased by 27% to $18.4 million from $14.5 million in the prior year quarter. The increase in costs was primarily due to an increase in salary expense, resulting from the renegotiation of multi-year physician contracts and the ramp-up in the number of personnel needed to meet the increasing demand for services in Beijing and Shanghai, as well as development and post-opening operating expenses related to the new clinic in Guangzhou, the pending clinic in Shanghai as well as increased direct patient care costs, costs allocated from the parent company and higher excise taxes.


Fiscal 2009 Outlook:


Lipson stated, "We continue to expect Medical Products revenue of $50-$55 million for the second half of fiscal 2009, as we should see considerable product shipments in the fourth quarter. For Healthcare Services, we anticipate that our full year revenue growth should be in the mid-twenty percent range. We are adjusting our growth rate expectation to account for the delay in opening the Shanghai Pudong Clinic and the later than expected start up of our Guangzhou clinic."


"Demand for our products and services remains strong and we have not seen an impact as a result of the world-wide financial crisis. Given the policies implemented by China in response to the crisis, we are optimistic that our business growth opportunities will not be substantially impacted by the current situation."


Fiscal 2009 Third Quarter Conference Call


Management will host a conference call today at 8:00 am ET to discuss financial results.


To participate in the conference call, international callers dial +1-719- 325-4757 and domestic callers dial 1-877-874-1568 approximately 10 minutes before the conference call is scheduled to begin.


The telephone replay will be available on the day of the call at (international) +1-719-457-0820 and (domestic) 1-888-203-1112 and continue to be available through February 23, 2009.


This call is also being webcast and will be accessible at Chindex's website http://ir.chindex.com/events.cfm . The event will be archived and available for replay through February 23, 2009.


About Chindex International, Inc.


Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,200 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, http://www.chindex.com and http://www.unitedfamilyhospitals.com .


Safe Harbor Statement


Statements made in this press release relating to plans, strategies, objectives, economic performance and trends and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the factors set forth under the heading "Risk Factors" in our annual report on Form 10-K for the year ended March 31, 2008, updates and additions to those "Risk Factors" in our interim reports on Form 10-Q, Forms 8-K and in other documents filed by us with the Securities and Exchange Commission from time to time. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue" or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We have no obligation to update these forward- looking statements.




                         CHINDEX INTERNATIONAL, INC.
                 CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
                 (in thousands except share and per share data)
                               (Unaudited)

                                 Three months ended      Nine months ended
                                    December 31,            December 31,
                                     2008        2007        2008        2007
    Product sales                 $21,070     $18,316     $52,607     $47,079
    Healthcare services
     revenue                       20,530      17,695      59,171      48,355
    Total revenue                  41,600      36,011     111,778      95,434

    Cost and expenses
     Product sales costs           15,493      13,131      38,576      34,417
     Healthcare services costs     17,185      13,724      49,586      37,693
     Selling and marketing
      expenses                      3,867       3,153       9,590       8,619
     General and administrative
      expenses                      3,158       2,069       9,728       6,792
    Income  from operations         1,897       3,934       4,298       7,913
    Other (expenses) and
      income
      Interest expense               (259)       (198)       (738)       (573)
      Interest income                 527         358       1,316         500
      Miscellaneous income
      (expense) - net                (661)       (124)     (1,257)       (171)
    Income before income taxes      1,504       3,970       3,619       7,669
    Provision for income taxes       (658)        (76)     (2,073)     (1,328)
    Net income                       $846      $3,894      $1,546      $6,341

    Net income per common
     share - basic
     Net income                     $0.06       $0.34       $0.11       $0.57
    Weighted average shares
     outstanding - basic       14,455,237  11,583,911  14,395,239  11,195,153

    Net income per common
     share - diluted
     Net income                     $0.05       $0.28       $0.10       $0.49
    Weighted average shares
     outstanding - diluted     15,836,521  14,126,348  16,089,705  13,037,838



                           CHINDEX INTERNATIONAL, INC.
                      CONSOLIDATED CONDENSED BALANCE SHEETS
                        (in thousands except share data)


                                         December 31, 2008    March 31, 2008
                                                (Unaudited)
                   ASSETS
    Current assets:
    Cash and cash equivalents                      $21,669           $79,258
    Restricted cash                                  1,979             1,123
    Investments                                     14,055                 0
    Trade accounts receivable, less
     allowance for doubtful accounts of
    $4,605 and $3,940, respectively
      Product sales receivables                     16,635            12,098
      Patient service receivables                    9,103             9,085
    Inventories, net                                 8,117             9,796
    Deferred income taxes                            2,037             1,656
    Other current assets                             6,212             3,294
      Total current assets                          79,807           116,310
    Investments                                     39,144                 0
    Restricted cash                                    818                 0
    Property and equipment, net                     20,510            18,428
    Noncurrent deferred income taxes                   104                 0
    Other assets                                     1,758             1,241
      Total assets                                $142,141          $135,979
    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
    Short-term debt, current portion of
     long-term debt and vendor financing              $970               $82
    Current portion of capitalized leases               31                36
    Accounts payable                                 8,016             9,938
    Accrued expenses                                10,481            11,064
    Other current liabilities                        3,371             3,571
    Deferred revenue                                 3,781               765
    Income taxes payable                               518               349
    Total current liabilities                       27,168            25,805
    Long-term debt, vendor financing and
     convertible debentures                         22,930            22,556
    Long-term portion of capitalized
     leases                                              0                22
    Long-term deferred tax liability                     0               208
      Total liabilities                             50,098            48,591
    Commitments and contingencies
    Stockholders' equity:
       Preferred stock, $.01 par value,
        500,000 shares authorized, none
        issued                                           0                 0
       Common stock, $.01 par value,
        28,200,000 shares authorized,
        including
       3,200,000 designated Class B:
    Common stock - 13,452,007  and
     13,074,593 shares issued and
     outstanding at December 31, 2008 and
     March 31, 2008, respectively                      135               131
    Class B stock - 1,162,500 shares
     issued and outstanding at December
     31, 2008 and March 31, 2008,
     respectively                                       12                12
       Additional paid in capital                   94,960            92,586
    Accumulated other comprehensive
     income                                          2,941             2,210
    Accumulated deficit                             (6,005)           (7,551)
    Total stockholders' equity                      92,043            87,388
    Total liabilities and stockholders'
     equity                                       $142,141          $135,979




                           CHINDEX INTERNATIONAL, INC.
                               SEGMENT INFORMATION


The Company operates in two businesses: Healthcare Services and Medical Products. The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes, not including foreign exchange gains or losses. The following segment information has been provided per Statement of Financial Accounting Standards No. 131, "Disclosures about Segments of an Enterprise and Related Information:" (in thousands except share data)


                                         Healthcare     Medical
                                           Services    Products         Total
    For the three months ended December
     31, 2008:
    Sales and service revenue                $20,530     $21,070      $41,600
    Gross Profit                                n/a *      5,577          n/a
    Gross Profit %                              n/a *        26%          n/a
    Income (loss) from operations before
     foreign exchange                         $2,142       $(630)      $1,512
    Foreign exchange gain                                                 385
    Income from operations                                             $1,897
    Other (expense), net                                                 (393)
    Income before income taxes                                         $1,504
    As of December 31, 2008:
    Assets                                   $95,984     $46,157     $142,141


                                          Healthcare     Medical
                                            Services    Products        Total
    For the three months ended December
     31, 2007:
    Sales and service revenue                $17,695     $18,316      $36,011
    Gross Profit                                n/a *      5,185          n/a
    Gross Profit %                              n/a *        28%          n/a
    Income from operations before foreign
     exchange                                 $3,220        $197       $3,417
    Foreign exchange gain                                                 517
    Income from operations                                             $3,934
    Other(expense), net                                                    36
    Income before income taxes                                         $3,970
    As of March 31, 2008:
    Assets                                   $93,727     $42,252     $135,979


                                          Healthcare     Medical
                                            Services    Products        Total
    For the nine months ended December
     31, 2008:
    Sales and service revenue                $59,171     $52,607     $111,778
    Gross Profit                                n/a *     14,031          n/a
    Gross Profit %                              n/a *        27%          n/a
    Income (loss) from operations before
     foreign exchange                         $5,970     $(2,185)      $3,785
    Foreign exchange gain                                                 513
    Income from operations                                             $4,298
    Other (expense), net                                                 (679)
    Income before income taxes                                         $3,619
    As of December 31, 2008:
    Assets                                   $95,984     $46,157     $142,141




                                          Healthcare     Medical
                                            Services    Products        Total
    For the nine months ended December
     31, 2007:
    Sales and service revenue                $48,355     $47,079      $95,434
    Gross Profit                                n/a *     12,662          n/a
    Gross Profit %                              n/a *        27%          n/a
    Income (loss) from operations before
     foreign exchange                         $8,057     $(1,003)      $7,054
    Foreign exchange gain                                                 859
    Income from operations                                             $7,913
    Other (expense), net                                                 (244)
    Income before income taxes                                         $7,669
    As of March 31, 2008:
    Assets                                   $93,727     $42,252     $135,979

    * Gross profit margins are not routinely calculated in the healthcare
      industry.

    For more information, please contact:

     Integrated Corporate Relations
     Ashley M. Ammon
     Tel: +1-203-682-8200
]]>
      
    
    
      [Press Release] Chindex International, Inc. to Participate in UBS Global Healthcare Services Con
      message_789
      03 Feb 2009 06:30:00 GMT
      http://chinasecurities.com/ir/ChindexInternational/messages/789
      
        Chindex International, Inc. to Participate in UBS Global Healthcare Services Conference

BETHESDA, Md., Feb. 3 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of western healthcare products and services in the People's Republic of China, today announced that the Company will attend the 2009 UBS Global Healthcare Services Conference, to be held at the Waldorf-Astoria in New York from February 9 to 11, 2009.


Management is currently scheduled to present at 10:00 am ET on Monday, February 9, 2009, and meet with institutional investors the same day.


A webcast of the presentation will be available on Chindex's website http://ir.chindex.com/events.cfm .


For more details on the conference, please contact your UBS institutional sales representative.


About Chindex International, Inc.


Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in the Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,200 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, http://www.chindex.com and http://www.unitedfamilyhospitals.com .


    For more information, please contact:

     Integrated Corporate Relations
     Ashley M. Ammon
     Tel: +1-203-682-8200
]]>
      
    
    
      [Press Release] Chindex International, Inc. to Report Fiscal Third Quarter 2009 Financial Result
      message_790
      29 Jan 2009 15:01:00 GMT
      http://chinasecurities.com/ir/ChindexInternational/messages/790
      
        BETHESDA, Md., Jan. 29 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq: CHDX - News), a leading independent American provider of western healthcare products and services in the People's Republic of China, today announced that it plans to release fiscal third quarter 2009 financial results on Monday, February 9, 2009, before market open. Management will host a conference call at 8:00 am ET that day to discuss financial results.


To participate in the conference call, international callers dial 1-719-325-4757 and domestic callers dial 1-877-874-1568 approximately 10 minutes before the conference call is scheduled to begin.


The telephone replay will be available on the day of the call at (international) 1-719-457-0820 and (domestic) 1-888-203-1112 and continue to be available through February 23, 2009.


This call is also being webcast and will be accessible at Chindex's website http://ir.chindex.com/events.cfm.  The event will be archived and available for replay through February 23, 2009.


About Chindex International, Inc.


Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in the Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,200 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, http://www.chindex.com and http://www.unitedfamilyhospitals.com.


Contact:  Integrated Corporate Relations


              Ashley M. Ammon
              (203) 682-8200

]]>
      
    
    
      [Press Release] Chindex International Inc. Announces Participation in the 2009 UBS Greater China
      message_791
      08 Jan 2009 15:00:00 GMT
      http://chinasecurities.com/ir/ChindexInternational/messages/791
      
        Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference


BETHESDA, Md., Jan. 8 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq: CHDX - News; "CHDX" or "the Company"), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced that the Company will attend the 2009 UBS Greater China Conference, to be held in Shanghai on January 12th and 13th.


The 2009 UBS Greater China Conference will be held at the Pudong Shangri- La hotel in Shanghai, China.  Management is currently scheduled to meet with institutional investors on January 12, 2009.


For more details on the conference, please contact your UBS institutional sales representative.


About Chindex International Inc.


Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong.  Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China.  The Company's hospital network currently operates in Beijing, Shanghai, Guangzhou and Wuxi.  The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively.  It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export- Import Bank and the German KfW Development Bank.  With twenty-seven years of experience, approximately 1,200 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities.  Further company information may be found at the Company's websites, http://www.chindex.com and http://www.unitedfamilyhospitals.com .


    For more information, please contact:

     Integrated Corporate Relations
     Ashley M. Ammon and Jeanne Dellicarri
     Tel: +1-203-682-8200
]]>